Asset Dedication’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$124K Hold
237
– – 0.01% 370
2026
Q2
$118K Hold
237
– – 0.01% 378
2026
Q1
$106K Sell
237
-57
-19% -$26.6K 0.01% 384
2025
Q4
$133K Hold
294
– – 0.01% 364
2025
Q3
$115K Buy
294
+19
+7% +$7.94K 0.01% 400
2025
Q2
$122K Buy
275
+71
+35% +$32.7K 0.01% 387
2025
Q1
$98.9K Sell
204
-10
-5% -$4.66K 0.01% 371
2024
Q4
$86.2K Buy
214
+12
+6% +$5.56K 0.01% 396
2024
Q3
$93.9K Hold
202
– – 0.01% 420
2024
Q2
$94.7K Buy
202
+100
+98% +$43.4K 0.01% 410
2024
Q1
$42K Hold
102
– – ﹤0.01% 472
2023
Q4
$42K Hold
102
– – ﹤0.01% 462
2023
Q3
$35K Buy
102
+58
+132% +$20.3K ﹤0.01% 478
2023
Q2
$15K Hold
44
– – ﹤0.01% 614
2023
Q1
$14K Buy
+44
New +$13.2K ﹤0.01% 625
2020
Q4
– Sell
-37
Closed -$10K – 822
2020
Q3
$10K Buy
+37
New +$10.2K ﹤0.01% 537
2016
Q4
– Sell
-42
Closed -$4K – 425
2016
Q3
$4K Buy
+42
New +$3.97K ﹤0.01% 360
2016
Q1
– Sell
-42
Closed -$5K – 650
2015
Q4
$5K Buy
+42
New +$5.07K ﹤0.01% 469

Other funds holding VRTX

Asset Dedication's VRTX Position: Q3 2026 in Review

Asset Dedication held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 237 shares worth $124K. The position accounts for 0.01% of the portfolio, ranked #370.

Asset Dedication first reported a position in VRTX in Q4 2015 and has held it in 18 quarters since. The position peaked at $133K in Q4 2025. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Asset Dedication held 237 shares of Vertex Pharmaceuticals worth $124K as of Q3 2026.
  • Asset Dedication left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up 0.01% of Asset Dedication's portfolio in Q3 2026, its #370 holding.
  • Asset Dedication first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 18 quarters since.
  • Asset Dedication's Vertex Pharmaceuticals position peaked at $133K in Q4 2025.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Asset Dedication's 13F filing for Q3 2026, filed 3 Nov 2026.